What Is Insulin Resistance?
Insulin resistance is a condition in which your body’s cells — primarily in muscle, liver, and fat tissue — do not respond normally to insulin. Insulin is the key that unlocks cells to allow glucose (blood sugar) to enter and be used for energy. When cells become resistant to that key, the pancreas compensates by producing more insulin. For a while, this works — blood sugar stays normal. But over time, the pancreas cannot keep up, blood sugar begins to rise, and the metabolic consequences accumulate.
Insulin resistance is one of the most common and clinically underrecognized drivers of weight gain and difficulty with weight loss. At Scale Solutions — led by physician Dr. Donald L. Gates, MD — we measure insulin resistance as part of our standard intake workup because addressing it directly changes treatment outcomes. Patients who leave other programs frustrated after months without progress often find that untreated insulin resistance was the missing variable.
How Insulin Resistance Is Measured
HOMA-IR: The Standard Clinical Tool
The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is the most widely used clinical tool for quantifying insulin resistance. It is calculated from two simple fasting blood values:
HOMA-IR = (Fasting Insulin [μIU/mL] × Fasting Glucose [mg/dL]) ÷ 405
A HOMA-IR below 1.0 is generally considered normal. Values between 1.0 and 1.9 suggest mild resistance; 2.0 and above indicates significant insulin resistance; and values above 2.9 are associated with severe insulin resistance and elevated risk of type 2 diabetes. These cutoffs can vary slightly by population and laboratory.
Fasting Insulin
A fasting insulin level alone provides useful information. Many patients have a normal fasting glucose but an elevated fasting insulin — meaning their pancreas is working extremely hard to keep blood sugar in range. This pattern, often called “compensated insulin resistance,” is a warning sign that is easy to miss when only glucose or A1c is checked. At Scale Solutions, we run fasting insulin as part of our standard lab panel — it is a routine test that most primary care offices do not routinely include.
Other Markers
Additional lab findings that suggest insulin resistance include:
- Elevated fasting triglycerides (particularly above 150 mg/dL)
- Low HDL cholesterol (below 40 mg/dL in men, below 50 mg/dL in women)
- Elevated A1c in the prediabetic range (5.7–6.4%)
- Elevated C-reactive protein (CRP) — a marker of the low-grade inflammation that often accompanies insulin resistance
- Waist circumference above 35 inches in women or 40 inches in men (a clinical proxy for visceral adiposity)
How Insulin Resistance Drives Weight Gain
Understanding this mechanism helps explain why some people gain weight far more easily than others eating the same food — and why standard low-calorie diets often fail people with significant insulin resistance.
Elevated Insulin Promotes Fat Storage
Insulin is the body’s primary anabolic hormone. In its fat storage role, it activates enzymes that move fatty acids into fat cells and inhibits enzymes that break stored fat down. Chronically elevated insulin — the compensatory response to insulin resistance — means the fat-storage signal is continuously active. The body is constantly being told to store, not burn.
Fat Mobilization Is Blocked
Lipolysis — the process of breaking down stored fat for energy — is powerfully suppressed by insulin. Even modestly elevated insulin levels between meals can blunt fat mobilization significantly. For someone with insulin resistance who is producing three to four times the normal amount of insulin to maintain blood sugar, periods of true fat burning may be brief or limited, even during caloric restriction.
Hunger Signals Are Disrupted
Insulin resistance in the brain — specifically in the hypothalamic circuits that regulate appetite — disrupts normal satiety signaling. The brain becomes less responsive to leptin (the fullness hormone) and may interpret stored energy as unavailable, triggering hunger even in the presence of significant fat reserves. This is why people with severe insulin resistance often report always being hungry and never feeling satisfied — their brain’s energy sensors are giving inaccurate readings.
The Carbohydrate-Insulin-Fat Cycle
For people with insulin resistance, refined carbohydrates create a particularly vicious cycle. A meal high in refined carbs produces a sharp spike in blood glucose. The resistant cells don’t absorb glucose efficiently, so blood sugar stays high. The pancreas produces a large insulin surge. Insulin drives what glucose it can into cells — but also drives excess glucose into fat storage. Blood sugar then drops sharply, triggering hunger again within 1–2 hours. The person eats again, repeating the cycle. Over time, this cycle drives progressive weight gain even at moderate total caloric intakes.
Why GLP-1 Agonists Address the Root
Standard calorie-restriction diets address the symptom (caloric surplus) without addressing the underlying biology (insulin resistance driving fat storage and hunger). GLP-1 receptor agonists — the class that includes semaglutide and tirzepatide — work on the root metabolic problem in several ways:
Direct Improvement in Insulin Sensitivity
GLP-1 agonists improve insulin sensitivity both directly and indirectly. Directly, they enhance glucose-dependent insulin secretion from the pancreas and reduce glucagon secretion, improving the insulin-to-glucagon ratio and normalizing glucose handling. Indirectly, meaningful weight loss — particularly loss of visceral and ectopic fat (fat in the liver and muscle) — reduces the metabolic inflammation and lipotoxicity that drive cellular insulin resistance.
Reduction of Hepatic Glucose Output
GLP-1 agonists suppress glucagon, which means the liver receives a smaller signal to release stored glucose. This helps normalize fasting blood sugar and reduces the overall insulin demand the pancreas must meet.
Reduction in Visceral and Ectopic Fat
GLP-1 medications produce preferential reductions in visceral adipose tissue and liver fat (hepatic steatosis is common in patients with insulin resistance). Reducing liver fat directly improves hepatic insulin sensitivity, which is often the dominant site of insulin resistance in overweight adults. This is a metabolic benefit that goes beyond what the scale number shows.
Appetite Normalization
By acting on hypothalamic GLP-1 receptors, these medications restore more appropriate appetite signaling — reducing the disproportionate hunger that insulin-resistant patients experience and making sustainable dietary reduction feasible for the first time in years.
The Lab Workup We Run
At Scale Solutions, our standard initial metabolic panel for a patient with suspected insulin resistance includes:
- Fasting glucose — baseline glycemic status
- Fasting insulin — enables HOMA-IR calculation
- HbA1c — 3-month average blood sugar, screens for prediabetes/diabetes
- Full lipid panel — triglycerides and HDL are metabolic syndrome markers
- Comprehensive metabolic panel (CMP) — liver and kidney function, electrolytes
- TSH (thyroid) — thyroid dysfunction can mimic or worsen metabolic resistance
- Complete blood count (CBC) — general health screen
- Uric acid — elevated uric acid is often elevated in insulin-resistant patients and helps guide dietary counseling
This panel is ordered before starting any medication and repeated at 3 months and 6 months to track improvement. Watching your HOMA-IR decline from, say, 4.2 to 1.8 over six months of treatment is some of the most motivating data we can show a patient.
Dietary Co-Strategy: Low-Carb Basics
Medication is most effective when paired with a dietary pattern that reduces the insulin demand the body must meet. For patients with insulin resistance, this means reducing refined carbohydrates — the primary driver of post-meal insulin surges.
We do not mandate a single dietary approach, but we do provide evidence-based guidance:
- Reduce refined carbohydrates and added sugars: White bread, white rice, pastries, sweetened beverages, and ultra-processed snacks are the priority targets. These foods produce rapid, high glucose and insulin spikes in insulin-resistant patients.
- Prioritize protein: Protein has minimal effect on blood sugar, supports muscle preservation during weight loss, and is highly satiating. We recommend 0.8–1.2 grams per kilogram of body weight per day depending on activity level.
- Include non-starchy vegetables liberally: These provide fiber, micronutrients, and volume without meaningful glycemic impact.
- Moderate healthy fats: Olive oil, avocado, nuts, and fatty fish support satiety without metabolic harm in the context of an overall caloric reduction.
- Limit liquid calories: Sugary drinks — including fruit juice, sweet tea, and soft drinks — are one of the highest-impact areas for insulin management in the Southern dietary pattern. Replacing these with water, unsweetened tea, or sparkling water is one of the single most effective changes.
Expected Timeline to Insulin Sensitivity Improvement
Patients frequently ask: how long before I see real metabolic change? While individual response varies, a general evidence-based timeline looks like this:
- Weeks 1–4: Fasting insulin often begins to decline as dietary carbohydrates are reduced and the medication’s direct pancreatic effects take hold. Some patients notice reduced hunger and better energy within 2–3 weeks.
- Weeks 4–12: With 5–10% body weight reduction, measurable improvements in fasting glucose and HOMA-IR are typically visible on repeat labs. Triglycerides often show early and dramatic improvement.
- 3–6 months: HbA1c changes become visible (it reflects a 3-month average). Patients with prediabetic A1c often move into the normal range. HDL cholesterol usually starts rising.
- 6–12 months: Liver fat (hepatic steatosis) measurably reduces with sustained weight loss, further improving insulin sensitivity. Many patients who started with HOMA-IR above 3.0 reach values below 2.0.
These improvements compound — better insulin sensitivity supports continued weight loss, which further reduces insulin resistance. This positive cycle is the metabolic goal.
If you are ready to understand your metabolic health at a deeper level and work with a physician who has been doing this since 1999, start with our medical weight loss program. We see patients at locations in Savannah, Pooler, and Hinesville. Call (912) 352-7546 to schedule your initial evaluation.
This page is for informational purposes only and is not medical advice. Consult Dr. Gates or another qualified clinician before starting any treatment.